All news

Barclays keeps Buy on AbbVie despite 0.8% target gap

Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash

Barclays analyst Emily Field maintained a Buy rating on AbbVie with a $325.00 price target, following quarterly revenue of

Read original source

ABBV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.